N Sawada1, M Inoue1,2, M Iwasaki1, T Yamaji1, T Shimazu1, S Sasazuki1, S Tsugane1. 1. Epidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan. 2. AXA Department of Health and Human Security, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Tokyo, Japan.
Abstract
BACKGROUND/ OBJECTIVES: Although vitamin D has been experimentally reported to inhibit tumorigenesis, cell growth and prostate cancer invasion, epidemiologic data regarding prostate cancer risk are inconsistent, and some studies have suggested positive but nonsignificant associations. Further, the impact of vitamin D on prostate cancer between Western and Japanese populations may differ due to different plasma vitamin D levels. SUBJECTS/ METHODS: We performed a nested case-control study within the Japan Public Health Center-based Prospective (JPHC) Study in 14,203 men (40-69 years) who answered a self-administered questionnaire at baseline (1990-1994) and gave blood samples, and were followed until 2005. We identified 201 prostate cancers which are newly diagnosed during follow-up (mean 12.8 years). We selected two matched controls for each case from the cohort. We used a conditional logistic regression model to estimate the odds ratios (ORs) and 95% confidence intervals (CIs) for prostate cancer with respect to levels of 25-hydroxy vitamin D (25(OH)D) in plasma. RESULTS: We did not observe statistically significant association between 25(OH)D level and total prostate cancer (multivariate OR=1.13 (95%CI=0.66-1.94, Ptrend=0.94) for the highest versus lowest tertile) However, 25(OH) levels were slightly positively associated with advanced cancer. The results remained substantially unchanged after stratification by intake of fish or calcium intake. CONCLUSIONS: 25(OH)D level showed no association with overall prostate cancer among Japanese men in this large cohort.
BACKGROUND/ OBJECTIVES: Although vitamin D has been experimentally reported to inhibit tumorigenesis, cell growth and prostate cancer invasion, epidemiologic data regarding prostate cancer risk are inconsistent, and some studies have suggested positive but nonsignificant associations. Further, the impact of vitamin D on prostate cancer between Western and Japanese populations may differ due to different plasma vitamin D levels. SUBJECTS/ METHODS: We performed a nested case-control study within the Japan Public Health Center-based Prospective (JPHC) Study in 14,203 men (40-69 years) who answered a self-administered questionnaire at baseline (1990-1994) and gave blood samples, and were followed until 2005. We identified 201 prostate cancers which are newly diagnosed during follow-up (mean 12.8 years). We selected two matched controls for each case from the cohort. We used a conditional logistic regression model to estimate the odds ratios (ORs) and 95% confidence intervals (CIs) for prostate cancer with respect to levels of 25-hydroxy vitamin D (25(OH)D) in plasma. RESULTS: We did not observe statistically significant association between 25(OH)D level and total prostate cancer (multivariate OR=1.13 (95%CI=0.66-1.94, Ptrend=0.94) for the highest versus lowest tertile) However, 25(OH) levels were slightly positively associated with advanced cancer. The results remained substantially unchanged after stratification by intake of fish or calcium intake. CONCLUSIONS: 25(OH)D level showed no association with overall prostate cancer among Japanese men in this large cohort.
Authors: José M Ordóñez-Mena; Ben Schöttker; Ulrike Haug; Heiko Müller; Josef Köhrle; Lutz Schomburg; Bernd Holleczek; Hermann Brenner Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-03-05 Impact factor: 4.254
Authors: Pentti Tuohimaa; Leena Tenkanen; Merja Ahonen; Sonja Lumme; Egil Jellum; Göran Hallmans; Pär Stattin; Sverre Harvei; Timo Hakulinen; Tapio Luostarinen; Joakim Dillner; Matti Lehtinen; Matti Hakama Journal: Int J Cancer Date: 2004-01-01 Impact factor: 7.396
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396